Metabolic 5 min read

Retatrutide — The Triple Agonist Re-Defining the Incretin Class

A GLP-1 / GIP / glucagon triple receptor agonist with the most dramatic weight-loss read-outs in any incretin trial to date. Mechanism, the published evidence, and what the literature still does not know.

Retatrutide (LY3437943) is Eli Lilly’s investigational triple agonist of the GLP-1, GIP and glucagon receptors. It is the most aggressive incretin molecule yet — engineered to activate all three receptors with roughly balanced potency — and the phase-2 data published in 2023 showed the largest mean weight loss ever reported in a randomised incretin trial.

The molecule is still in late-stage clinical development. It has not been authorised by the MHRA, the EMA, the FDA or any other medicines regulator, and is not available on the NHS or as a private prescription. It can only be handled as a research compound for in-vitro work, and labs using it should price that constraint into their protocols. The published literature is nevertheless rich enough to deserve a proper look.

What it is

Retatrutide is a 39-residue fatty-acid-modified peptide derived from a glucagon backbone. The fatty-acid (C20 diacid) chain anchors the molecule to serum albumin in plasma — the same trick that gives semaglutide and tirzepatide their once-weekly dosing profiles. In retatrutide's case the PK is even slower: phase-2 data report an elimination half-life of approximately ~6 days.

The three receptors it targets:

GLP-1 receptor (GLP-1R). Drives most of the appetite-suppression and insulin-secretion signal that defines the modern incretin drugs.
GIP receptor (GIPR). Adds metabolic and adipose-tissue effects poorly captured by GLP-1 alone — the basis of the additional weight loss seen with tirzepatide vs semaglutide.
Glucagon receptor (GCGR). The genuinely novel addition. Glucagon agonism increases energy expenditure and hepatic fat oxidation, which is plausibly what drives the dramatic body-composition shift seen in retatrutide trials.

The trick — and the engineering hard part — is balancing all three activities. A receptor-skewed analogue would either fail (GCGR domination causing hyperglycaemia) or simply look like a slightly tweaked GLP-1 / GIP molecule. Retatrutide's PD profile is close to equipotent across all three at clinical doses.

What the clinical literature actually shows

The defining publication is the phase-2 obesity trial (Jastreboff et al., NEJM, 2023):

N = 338 adults with BMI ≥ 30, randomised to placebo or one of four retatrutide doses (1 mg, 4 mg, 8 mg, 12 mg) once weekly for 48 weeks.
Placebo-adjusted mean weight loss at 48 weeks: −6.5% (1 mg), −13.5% (4 mg), −19.5% (8 mg), −22.1% (12 mg).
Approximately a quarter of the 12 mg group lost ≥ 30% of body weight by week 48. Nothing in the GLP-1 era has come close.

The companion phase-2 trial in type-2 diabetes (Rosenstock et al., Lancet, 2023) showed substantial HbA1c reductions across the same dose range with weight loss as a co-primary endpoint, broadly consistent with the obesity data.

Mechanism beyond "all three at once"

The interesting story is why triple agonism does what dual agonism doesn't:

Energy expenditure. Glucagon agonism modestly increases resting energy expenditure, an effect absent from GLP-1 and GIP. Across 24 weeks this swings the energy balance equation.
Hepatic lipid oxidation. Sub-studies show preferential reduction in liver-fat content above what would be predicted by weight loss alone, consistent with direct hepatic glucagon signalling.
Adipose remodelling. Body-composition sub-studies show a slightly higher fat-mass-to-lean-mass ratio of loss than tirzepatide at equivalent total weight loss — meaning the loss is more "fat-mass weighted" rather than the lean-mass spill that traditionally limits aggressive caloric restriction.

The glucagon component is also the bit that needs the most engineering care: too much GCGR activity causes hyperglycaemia and hepatic glucose output, which is why purely-GCGR-skewed analogues have historically failed. Retatrutide's GLP-1 / GIP activity appears to neutralise the glycaemic downside in the trial population.

What we don't know

Cardiovascular outcomes. Phase-3 cardiovascular outcome trials (the data that determined GLP-1 prescribing) are pending.
Long-term safety beyond 48 weeks. All published trials are short by chronic-disease standards.
Effect on lean mass at very high doses or in older participants. Body-composition data so far is reassuring but skewed towards middle-aged adults.
Weight regain after discontinuation. Likely similar to the GLP-1 class (significant) but unquantified.

Half-life and stability

The serum-albumin-bound mechanism produces a ~6 day half-life in humans, supporting once-weekly subcutaneous dosing. Pre-clinical animal half-lives are shorter because albumin biology differs across species.

Lyophilised retatrutide is stable at -20 °C for the long term, at 2–8 °C for shipping windows, and at room temperature for short transit. After reconstitution, refrigerated stability is typically rated for 28–30 days based on related GLP-1 analogues.

Quality matters more here, not less

Because retatrutide is engineered to bind three receptors, a synthesis error that subtly changes one receptor’s affinity can shift the entire PD balance — and the dose-response will look completely different. For in-vitro receptor work, <99% purity is not adequate. Pharma Tides supplies retatrutide at >99% HPLC purity with batch-specific COAs and ESI-MS verification on every order; the product page carries 5 mg and 10 mg vials with free tracked delivery.